CFI Variants Modulating Complement System Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dysregulated Complement Factor I (CFI) has been implicated in diseases involving the complement system, necessitating methods for modulating or inhibiting specific points of regulation within the complement system.
Innovation Solution
The development of CFI variants with modifications such as deletions, substitutions, and insertions of amino acid residues or domains, which enhance characteristics like activity, substrate specificity, and bioavailability, thereby modulating the complement system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If wild type CFI is used to regulate the complement system, then physiological complement regulation is achieved, but the half-life and bioavailability are insufficient for effective therapeutic modulation
Solution Approach 1:
The patent applies parameter changes by modifying amino acid residues in the CFI protein sequence to alter its pharmacokinetic properties. Specifically, mutations are introduced to increase half-life and bioavailability while maintaining complement regulatory function, transforming the protein's temporal characteristics for therapeutic effectiveness.
Solution Approach 2:
The patent creates composite protein structures by fusing CFI with albumin or other carrier proteins. This composite construction extends the half-life of CFI in circulation and improves its bioavailability, allowing sustained therapeutic modulation of the complement system that wild type CFI cannot achieve alone.
2Reliability
If CFI activity is increased to enhance complement regulation, then disease-related over-activity is reduced, but non-specific cleavage and off-target effects may increase
Solution Approach 1:
The patent applies local quality by making site-specific amino acid substitutions in the CFI protein that selectively enhance activity toward specific substrates (C3b, C4b) while preserving specificity. The modifications are localized to regions that influence substrate recognition and binding, allowing enhanced regulation without increasing non-specific cleavage.
Solution Approach 2:
The patent uses albumin or other carrier proteins as intermediaries that bind to CFI and modulate its activity. This intermediary interaction enhances CFI's therapeutic efficacy and stability while the carrier protein helps maintain specificity by controlling CFI's conformational state and substrate accessibility.
3Productivity
If CFI variants with modified amino acid sequences are developed to improve activity and specificity, then therapeutic potential is enhanced, but protein stability and structural integrity may be compromised
Solution Approach 1:
The patent carefully selects amino acid substitutions that change local chemical properties to enhance activity while preserving overall protein stability. The modifications are chosen to maintain disulfide bond formation, proper folding, and structural integrity while improving catalytic efficiency and substrate specificity.
Solution Approach 2:
The patent stabilizes modified CFI variants by fusing them with albumin or other stable carrier proteins. This composite structure provides a stable framework that maintains the integrity of the modified CFI while enhancing overall protein stability, half-life, and resistance to degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These CFI variants demonstrate improved activity and specificity in cleaving C3b and C4b, leading to enhanced regulation of the complement system, potentially reducing disease-related over-activity or dysregulation.
Implementation Method 1
CFI is one such regulator, and acts to regulate the complement system by cleaving C4b and C3b proteins, thereby inactivating these proteins
Implementation Method 2
The light chain (also referred to as the B chain) comprises the serine protease domain (SPD) responsible for the cleavage of C3b and C4b, and contains a catalytic triad (His362, Asp411, and Ser507) within a region referred to as the active site
Data Source
AI summary
Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.